primary liver cancer
Conditions
Interventions
Control group:Targeted immunotherapy after TACE
ß-1,3/a-1,3-glucan experimental group:Oral ß-glucan on the basis of TACE combined with targeted immunotherapy
Sponsors
The First People's Hospital of Qinzhou
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for primary liver cancer; 2. All patients with liver cancer were in the initial stage and had not received any other treatment before surgery; 3. All patients had no immune diseases and had not used immune enhancers, immune modulators, antibiotics, probiotics, etc. within one week before TACE; 4. All patients underwent imaging examinations such as CT or MRI, which ruled out distant metastasis. There were indications for TACE surgery; 5. 18 years <age<75 years.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with severe primary diseases of the cardiovascular, pulmonary, renal, cerebral, endocrine and hematopoietic systems, as well as patients with mental illnesses; patients complicated with other severe infectious diseases such as pulmonary tuberculosis and acquired immunodeficiency syndrome (AIDS), etc.; 3. Patients with active autoimmune diseases or other immune system diseases; 4. Patients who have previously received other anti-tumor treatments, such as systemic therapy, chemotherapy combined with radiotherapy, etc.; 5. Patients complicated with other malignant tumors or symptomatic brain metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor Markers;Liver Function; | — |
Secondary
| Measure | Time frame |
|---|---|
| cytokines;Complete Blood Count;immune cells subsets;T cell exhaustion markers;Immunoglobulin;gut microbiota; | — |
Countries
China
Contacts
Public ContactYuanli Wang
The First People's Hospital of Qinzhou
Outcome results
None listed